Ann: Quarterly Update and Appendix 4C, page-36

Again it was a deal that was commensurate with the small bank of the company.

But when MD was banging on like 1102 was the next Tysabri to the point of releasing ASX updates just on Tysabri's quarterly sales figures .... (plenty here would love those kind of updates now with all the fluffy pumps of late) .... and to then deal out 1102 to Teva for $2M up-front and potentially $100M in heavily back ended milestones seems to come across nothing like the type of deal they were implying.

It's not a bad deal - it's just commensurate - gives them a relatively risk free shot at a little piece of the pie.